Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.

× No keyword cloud information.

34 in total

1. Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity.

Authors: Diane N Singhroy; Mark A Wainberg; Thibault Mesplède
Journal: Antimicrob Agents Chemother Date: 2015-02-09 Impact factor: 5.191

2. Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.

Authors: Kristen N Andreatta; Derrick D Goodman; Michael D Miller; Kirsten L White
Journal: Antimicrob Agents Chemother Date: 2015-03-30 Impact factor: 5.191

3. Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings.

Authors: Robin M Nance; Vani Vannappagari; Kimberly Smith; Catherine B Johannes; Brian Calingaert; Catherine W Saltus; Kenneth H Mayer; Bridget M Whitney; Benigno Rodriguez; Richard D Moore; Joseph J Eron; Elvin Geng; William Christopher Mathews; Michael J Mugavero; Michael S Saag; Mari M Kitahata; Joseph A C Delaney; Heidi M Crane
Journal: J Acquir Immune Defic Syndr Date: 2019-08-15 Impact factor: 3.731

Review 4. Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

Authors: R Martin-Iguacel; J M Llibre; N Friis-Moller
Journal: Curr HIV/AIDS Rep Date: 2015-12 Impact factor: 5.071

5. Brief Report: Factors Associated With the Selection of Initial Antiretroviral Therapy From 2009 to 2012.

Authors: Michael S Saag; Andrew O Westfall; Stephen R Cole; William C Mathews; Daniel R Drozd; Kenneth H Mayer; Greer A Burkholder; Mari Kitahata; Eric M Maiese
Journal: J Acquir Immune Defic Syndr Date: 2017-01-01 Impact factor: 3.731

6. Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.

Authors: Hortensia Álvarez; Ana Mariño; Nieves Valcarce; Jesús García-González; Helena Díaz-Cambre; Josep M Llibre
Journal: Infection Date: 2018-08-25 Impact factor: 3.553

7. HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study.

Authors: Robin M Nance; J A Chris Delaney; Jane M Simoni; Ira B Wilson; Kenneth H Mayer; Bridget M Whitney; Frances M Aunon; Steven A Safren; Michael J Mugavero; W Christopher Mathews; Katerina A Christopoulos; Joseph J Eron; Sonia Napravnik; Richard D Moore; Benigno Rodriguez; Bryan Lau; Rob J Fredericksen; Michael S Saag; Mari M Kitahata; Heidi M Crane
Journal: Ann Intern Med Date: 2018-08-21 Impact factor: 25.391

8. The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.

Authors: Rima Kulkarni; Rebecca Hluhanich; Damian M McColl; Michael D Miller; Kirsten L White
Journal: Antimicrob Agents Chemother Date: 2014-08-04 Impact factor: 5.191

9. Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.

Authors: Kristen N Andreatta; Michael D Miller; Kirsten L White
Journal: Antimicrob Agents Chemother Date: 2015-11-16 Impact factor: 5.191

Review 10. Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.

Authors: Walter Dehority; Jacobo Abadi; Andrew Wiznia; Rolando M Viani
Journal: Drugs Date: 2015-09 Impact factor: 9.546